Dr Maurits Kleijnen

Chief Technology Officer at Intract Pharma Ltd

Speaker

Dr Kleijnen is Chief Technology Officer at Intract Pharma, London, UK. He did his BS/MS at Utrecht University which included one year of research at MIT’s Center for Cancer Research on immune evasion by cytomegalovirus. After obtaining a Harvard PhD in Virology, with a focus on papillomavirus-mediated oncogenesis, he did a postdoc in the Department of Cell Biology at Harvard Medical School studying ubiquitination and proteasome biology. Dr Kleijnen then moved to Imperial College London to set up his own lab as PI in the Centre for Haematology, with a focus on understanding the cell biology underlying multiple myeloma’s susceptibility to proteasome inhibitor exposure. After 8 years at Imperial, he then worked for 4 years as Group Leader at Immunocore, developing soluble T cell receptor-based bispecific therapeutics. Subsequently, he became Head of Research at a company generating VHH-based antibody bispecifics, before becoming Head of Research - and currently Chief Technology Officer - at Intract Pharma. Here, he invented and is developing the UTAC bispecific technology presented in his presentation.